B3(ds-scFv)靶向超抗原的制备及活性鉴定

To construct the expression vector of a recombinant toxin composed of a disulfide stable single-chain antibody from mAbB3 and SEA(D227A),the binding ability and cytotoxicity of the purified renatured products against the B3 positive carcinoma cells was examined. The VH and VL fragments of the mAbB3 were ligated by overlap PCR, the PCR product was cloned to the pET22b expression vector, then the SEA fragment was inserted into the B3dsscFv-pET22b expression vector which was digested by the same restriction enzymes. The expression plasmid was identified by restriction endonucleases digestion and transformed into E.coli BL21(DE3) followed by IPTG induction. The inclusion body was purified through SP-Sepharose cation exchange column after denaturing and refolding and the binding and cytotoxic ability of the purified products was examined by cell-ELISA and non-radioactive cell proliferation assay seperately. The expression vector B3dsscFv-SEA-pET was constructed successfully and the expression product exists mainly in the inclusion body, amounting to 33% of the total protein. The refolding product remains the binding ability of the single-chain antibody and has cytotoxic effect on HT-29 colon carcinoma cells. The stability assay showed that the resulting protein was stable at 37℃. This genetically engineered B3dsscFv-SEA fusion protein has bifunction of tumor targeting and tumor cell killing and promises to be an effective reagent for tumor targeted immunotherapy.

Preparation and Evaluation of B3(ds-scFv) Targeted SEA

To construct the expression vector of a recombinant toxin composed of a disulfide stable single-chain antibody from mAbB3 and SEA(D227A),the binding ability and cytotoxicity of the purified renatured products against the B3 positive carcinoma cells was examined. The VH and VL fragments of the mAbB3 were ligated by overlap PCR, the PCR product was cloned to the pET22b expression vector, then the SEA fragment was inserted into the B3dsscFv-pET22b expression vector which was digested by the same restriction enzymes. The expression plasmid was identified by restriction endonucleases digestion and transformed into E.coli BL21(DE3) followed by IPTG induction. The inclusion body was purified through SP-Sepharose cation exchange column after denaturing and refolding and the binding and cytotoxic ability of the purified products was examined by cell-ELISA and non-radioactive cell proliferation assay seperately. The expression vector B3dsscFv-SEA-pET was constructed successfully and the expression product exists mainly in the inclusion body, amounting to 33% of the total protein. The refolding product remains the binding ability of the single-chain antibody and has cytotoxic effect on HT-29 colon carcinoma cells. The stability assay showed that the resulting protein was stable at 37℃. This genetically engineered B3dsscFv-SEA fusion protein has bifunction of tumor targeting and tumor cell killing and promises to be an effective reagent for tumor targeted immunotherapy.